Definitive Contract 75N91025C00038
Award Date
9/5/25
Potential Completion Date
9/4/26
Potential Value
$355K
Federal Agency
National Cancer Institute
Awardee
Metaclipse Therapeutics Corp
Ultimate Awardee
Not listed
NAICS Category
541713 - Research and Development in Nanotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Doraville, GA 30340, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
55
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI), a civilian agency, to Pathcision Medicine, Inc., a minority-owned, woman-owned small business. The $354,941 firm-fixed-price contract is for the development of a novel delivery approach to transform the treatment and prevention of metastatic pancreatic cancer. The award is associated with a pre-solicitation opportunity that will focus on the development of innovative technologies for the...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI), a civilian agency, to Qana Therapeutics Inc. The $354,672 Firm Fixed Price contract is for the development of therapeutic technologies targeting ferroptosis inducers for the treatment of adrenocortical carcinoma, a rare cancer type. The contract is part of the NCI's SBIR Innovative Concept Award Program, which seeks innovative and potentially transformative technologies for the...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. The $355,000 Firm Fixed Price contract was awarded to Insilicom LLC, a minority-owned and woman-owned small business, to develop a proof-of-concept technology for drug repurposing targeting rare cancers using a large-scale, high-quality biomedical knowledge graph. The original contract opportunity was a...
This is a $355,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Petri Bio Inc., a small business, under the Small Business Innovation Research (SBIR) Phase I program. The contract is for the development of engineered microbial therapeutics for the treatment of heritable forms of glioma, a type of brain cancer. The work is focused on demonstrating technical feasibility and proof-of-concept for this therapeutic technology....
The National Cancer Institute awarded Nzumbe Inc. a $355,000 firm fixed price definitive contract under the Small Business Innovation Research Concept Award program. This program seeks proposals from small businesses for innovative concepts to advance pediatric and rare cancer therapies, diagnostics, or preventatives. Specifically, Nzumbe will demonstrate technical feasibility and proof-of-concept for a highly innovative pediatric or rare cancer idea through preliminary experiments, while also...
This is a Phase I SBIR contract award from the National Cancer Institute (NCI) to Tranquility Biodesign LLC, a small business, for the development of a novel engineered bacterial anticancer immunotherapy for Merkel cell carcinoma. The contract, valued at $354,996.00, was awarded under a total small business set-aside solicitation seeking proposals for the development of therapeutic, device, or diagnostic technologies for the treatment, detection, and diagnosis of pediatric cancers and rare...
This is a $289,828.00 SBIR Phase I contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Nicolalde R&D LLC, a minority-owned, self-certified small disadvantaged business. The contract is a firm fixed-price definitive contract with a completion date of November 30, 2021. The SBIR (Small Business Innovation Research) Program Phase I award indicates this contract is for early-stage research and development activities. As a...